This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

New Cancer Vaccine the Next Dendreon?

BOSTON ( TheStreet) -- Think all cancer vaccines are, or will be, successful? Think again.

Before there was Dendreon (DNDN) and its just-approved prostate cancer vaccine Provenge, there was Cell Genesys and Favrille, CancerVax and Genitope (GTOP.PK). All tried to develop cancer vaccines, all failed.

Dendreon's stock price is surging; those other four cancer vaccine companies -- not so much. Favrille and CancerVax are no longer with us. Genitope exists in pink sheet purgatory. Only Cell Genesys managed to survive, sort of, by selling itself to BioSante Pharmaceuticals (BPAX), a small drug company better known for trying to develop a female Viagra.

Dendreon is a great success story and proves that patience and perseverance can pay off in the fledgling field of cancer immunotherapy. But let's not also forget that Dendreon is a lonely winner surrounded by a crowd of cancer vaccine losers.

In the next weeks and months, investors are going to be enticed by drug companies crawling out of the woodwork with claims that they're working on the next Provenge. That's an easy thing to say, much tougher to actually accomplish.

Biotech investors are busy looking for the "next Dendreon." Nothing wrong with searching for new cancer vaccines, as long as investors remember that, once upon a time, some other investors bought Favrille and Genitope, CancerVax and Cell Genesys confident that they already owned the next Dendreon.

It didn't quite work out that way, unfortunately.

On Monday, BioSante said it was resurrecting the GVAX prostate cancer vaccine program that caused Cell Genesys to blow up in 2008.

Too new to the cancer vaccine game to remember what happened to Cell Genesys and GVAX? Here's a quick history lesson. Independent data safety monitors in August 2008 forced Cell Genesys to shutter one phase III clinical trial of GVAX because prostate cancer patients treated with GVAX and chemotherapy were dying at a faster rate than those patients treated with chemotherapy alone.

Cell Genesys stopped the second and final GVAX phase III study in October 2008 due to futility, meaning GVAX was deemed too ineffective to benefit prostate cancer patients.

GVAX was doomed from the start because data from phase II studies of the cancer vaccine were fairly lousy. Of course, that didn't stop Cell Genesys from signing a partnership with the Japanese drug maker Takeda, or for investors who thought they knew better to lose all their money when Cell Genesys' stock price sank to mere pennies.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
BPAX $55.05 -1.24%
DNDN $0.06 -6.02%
AGEN $8.61 0.00%
CVM $0.66 0.00%
AAPL $126.44 0.00%

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs